Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Carbon Dioxide Incubator Market Projected to Reach $1,284.66 million by 2030 -…
"Global Surge in Carbon Dioxide Incubators Fuels Progress in Health and Science" "Global Surge in Carbon Dioxide Incubators Fuels Progress in Health and Science" Carbon dioxide incubators are essential in advancing cell biology, pharmaceuticals, and cutting-edge medical research. These sophisticated devices are ideal as they have fine-tuned humidity, temperature, and carbon dioxide levels for cultivating cell cultures, playing a crucial role in life-saving research and…
PR Newswire
29/03/2024
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for…
Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 advancing toward interim analysis planned in 2024Orexin Agonist Program: Clinical proof-of-concept data for ORX750 in sleep-deprived healthy volunteers planned in 2024 LockBody ®Technology Platform: Ongoing Phase 1/2a study of LB101 (PD-L1xCD47)for the treatment of solid tumors BOSTON and LONDON, March28, 2024(GLOBE NEWSWIRE) --...
Nasdaq GlobeNewswire
28/03/2024
Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results
In discussing the results, Todd R. Nelson Ph.D., Founder and CEO of Telesis Bio said, “I'm pleased with our operating execution in a challenging macro environment during 2023. Our company experienced record BioXp kits sales and expanding gross margin against the backdrop of significant cost cutting initiatives undertaken to align our operating structure with our strategic vision for growth. We believe that our rapid and flexible mRNA synthesis kits are game-changing and unlock tremendous...
Nasdaq GlobeNewswire
28/03/2024
Galapagos publishes 2023 annual report and announces Annual and Extraordinary…
Publication of annual report for financial year 2023Annual Shareholders' Meeting resolutions include approval of revised Remuneration Policy and (re)appointment of Board membersExtraordinary Shareholders' Meeting resolutions include approval of renewal of authorized capital and issuance of Gilead Subsequent Warrant B Mechelen, Belgium; 28 March 2024, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial...
Nasdaq GlobeNewswire
28/03/2024
Oxurion Receives Transparency Notification from Atlas Special Opportunities…
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – March 28, 2024 – 07:00 PM CETOxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1it has received transparency notifications as follows: Oxurion received a transparency notification on March 27, 2024, from Atlas Special Opportunities, LLC indicating that as of March 19, 2024, it...
Nasdaq GlobeNewswire
28/03/2024
FullCare Medical starts medical garment production at Tatu City, Kenya
The FullCare Medical facility represents an investment of USD 30 million and employs 1,800 Kenyans in the first phase. In subsequent phases, the company plans to employ up to 7,000 Kenyans. The FullCare Medical facility represents an investment ofUSD 30 millionand employs 1,800 Kenyans in the first phase. In subsequent phases, the company plans to employ up to 7,000 Kenyans. "Our selection ofKenyaand Tatu City SEZ for our investment reflects our belief in the transformative power of...
PR Newswire
28/03/2024
Endoscopy Equipment Market Worth $46.2 billion | MarketsandMarkets™
Browse in-depth TOC on "Endoscopy Equipment Market" Browse in-depth TOC on "Endoscopy Equipment Market" 740 - Tables59 - Figures 604 - Pages Endoscopy Equipment Market Scope: Canada • Europe Germany UK France Spain Italy Rest of Europe • Asia Pacific China Japan India Australia South Korea Rest of Asia Pacific (RoAPAC) • Latin America Brazil Mexico Argentina Rest of...
PR Newswire
28/03/2024
DoH Collaborates with Eli Lilly and World Obesity Federation on Obesity…
The MoU was signed by H.E. Dr. Noura Al Ghaithi, Undersecretary of the DOH, Johanna Ralston, Chief Executive Officer at WOF and Irina Zaporozhets, President and General Manager, Middle East and Türkiye (META) Hub at Eli Lilly Suisse SA. Leveraging the parties' diverse expertise, Abu Dhabi will spearhead a multisectoral initiative to bridge the gaps that have hindered efforts to reduce obesity for many years. This collaboration will focus on empowering healthcare professionals with the skills to…
PR Newswire
28/03/2024
ZEISS Sets Stage for Future of Ophthalmic Surgery and 3D Visualization at ASCRS…
The future of 3D visualization in ophthalmic surgery The future of 3D visualization in ophthalmic surgery ZEISS is extending its workflow offerings with new surgical and visualization technologies at ASCRS. The ARTEVO ®850 3D heads-up ophthalmic microscope from ZEISS , used in both anterior and posterior surgical cases, is setting the pace in digital visualization with true color imaging thanks to the HDR monitor and two4K3-chip cameras, allowing the surgical field to be displayed...
PR Newswire
28/03/2024
New Publication: Racial Difference in Detection Rate of Bladder Cancer Using…
Overall, 2379 separate samples were identified from 1292 patients, of whom, 1095 (85%) were White/Caucasian, 96 (7%) Black/African American, 51 (4%) Asian and 50 (4%) Hispanic. The sensitivity of WLC, BLC, and the combination of both for any malignant lesion was 88.7%, 95.8% and 99%, respectively, in the total cohort (P<0.001). BLC sensitivity vs. WLC was most significantly pronounced in the Asian population (96% vs 78%, P<0.001). In all races, the sensitivity of BLC was significantly…
PR Newswire
28/03/2024
Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder…
David Norton Assumes Role of Interim Board Chair while the Company Runs a Global Search for a New Chair David Norton, lead independent director on the Compass board of directors, will become interim chair. Compass is running a global search for a permanent board chair, focused on recruiting a leader with a strong background in the biotechnology sector and broad strategic experience across the product lifecycle.“When we started Compass eight years ago, we could not have imagined how the...
Nasdaq GlobeNewswire
28/03/2024
Tigermed Reports Full Year 2023 Results
Business Highlights Business Highlights Tigermed continued to empower pharmaceutical and medical device innovation in 2023 and navigated the complexities of the life science sector, solidifying its leading position in the clinical CRO industry. From 2004 to 2023, Tigermed provided services to 61% of all Class I new drug approvals inChina. During the reporting period, Tigermed assisted in the approval of 22 Class I new drugs and 6 innovative medical devices inChina. Additionally,...
PR Newswire
28/03/2024
Nexstim Plc: Resolutions of the Annual General Meeting of Shareholders
Company Announcement, Helsinki, 28 March 2024 at 1 PM (EET) Nexstim Plc: Resolutions of the Annual General Meeting of Shareholders Nexstim Plc (NXTMH:HEX) (“Nexstim” or “Company”), announces as follows regarding the resolutions that were adopted at its Annual General Meeting of Shareholders held today on 28 March 2024. 1 PRESENTATION OF THE ANNUAL ACCOUNTS AND CONSOLIDATED ACCOUNTS, RESULT OF THE FINANCIAL YEAR AND DISCHARGE FROM LIABILITY. The annual general meeting adopted the...
Nasdaq GlobeNewswire
28/03/2024
Diverse Investment Avenues Await in the Booming Artificial Preservative Market…
Download the Sample PDF report to explore key market insights and trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-19352 Download the Sample PDF report to explore key market insights and trends:https://www.futuremarketinsights.com/reports/sample/rep-gb-19352 Driving Factors: Artificial Preservative Industry The rising demand for meat products. Meat has a short useful life and is highly perishable, which makes it difficult to transport and package without the...
PR Newswire
28/03/2024
Rice Water Skincare Market foresees a Sluggish Road in the Foreseeable Future…
Download the Sample PDF report to explore key market insights and trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-19355 Download the Sample PDF report to explore key market insights and trends:https://www.futuremarketinsights.com/reports/sample/rep-gb-19355 The rice water skincare market sees economic growth as consumers propel natural and traditional beauty remedies for their skincare routines. The popularity of rice water skincare products has pushed upwards...
PR Newswire
28/03/2024
Collagen Water Market to Reach $10.76 Billion by 2034 Fueled by Beauty and…
Download the Sample PDF report to explore key market insights and trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-19357 Download the Sample PDF report to explore key market insights and trends:https://www.futuremarketinsights.com/reports/sample/rep-gb-19357 The growing cosmetic and personal care industry is the fundamental driving force for the subject market. As collagens have better coagulation with different solvents, they create a better moisturizing base...
PR Newswire
28/03/2024
Isotopia Molecular Imaging Ltd. is thrilled to announce that Isoprotrace®, has…
Isotopia is a radiopharmaceutical focused company with proven expertise in developing, manufacturing, and commercializing pioneering diagnostic and therapeutic products, serving the nuclear medicine market. We appreciate Billev Pharma support as our marketing authorization holder. Isoprotrace® is designed to address prostate cancer patients. Isoprotrace® is indicated* for positron emission tomography (PET) in patients with prostate cancer, for primary staging of those with high-risk...
PR Newswire
28/03/2024
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
“Dr. Gallagher is the sixth director to join our board of directors in the past twelve months as we continue to refresh and strengthen the Board governance and oversight required for the next stage of the Company's development and growth,” said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. “His experience and leadership in leading multiple development programs through to global regulatory approval will support our efforts to rapidly advance our '5 by 5' programs into...
Nasdaq GlobeNewswire
28/03/2024
ACTREC Researchers Show Cancer Treatments May be Promoting its Spread
In a step towards these efforts, Prof. Indraneel Mittra from the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), India, has shed light on what causes metastasis. In a step towards these efforts, Prof.Indraneel Mittrafrom the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC),India, has shed light on what causes metastasis. Prof. Mittra's group focuses on cell-free chromatin particles (cfChPs)—small structures composed of DNA fragments...
PR Newswire
28/03/2024
Orexo publishes the Annual and Sustainability Report for 2023
Since 2017, Orexo has been supporting the UN Global Compact's principles and goals for a sustainable development for people and societies. Orexo's ambitious sustainability work, together with the efforts fighting the US opioid epidemic, recently shaped a new social financing framework for the company, including the issue of a new social bond on March 13, 2024. The new bond ensures the refinancing of the outstanding bond. Since 2017, Orexo has been supporting the UN Global Compact's principles...
PR Newswire
28/03/2024
Inventiva announces the nomination of Andre Turenne as Director
Daix (France), Long Island City (New York, United States), March 28, 2024– Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs, today announced the nomination of Andre Turenne to its Board of…
Nasdaq GlobeNewswire
28/03/2024
Sequana Medical announces 2023 Full Year Results and 2024 Outlook
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION28 March 2024, 08:00 a.m. CETalfapump® – PMA 1submitted to US FDA and accepted for substantive review, extensive feedback just received from FDA which is currently under review by the CompanyDSR® – potential treatment for cardiorenal syndrome in heart failure presented at international heart failure conference, strong data from non-randomized cohort of US MOJAVE studyGhent,...
Nasdaq GlobeNewswire
28/03/2024
Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine…
The companies will leverage their combined experience in the development of conjugate vaccines for their clients Primrose Bio will supply its industry-leading carrier protein, PeliCRM197 ®, for vaccine developmentIntravacc has IP and know-how in vaccine conjugation and manufacturing of carrier protein based productsClients active in conjugate vaccines will benefit from a seamless solution across development and manufacturingBILTHOVEN, The Netherlands, March28, 2024(GLOBE...
Nasdaq GlobeNewswire
28/03/2024
Casino Group: Successful implementation of Casino Group's financial…
Successful implementation of Casino Group's financial restructuring Paris, 28 March 2024Casino, Guichard-Perrachon (" Casino ") announces the effective completion of its financial restructuring.All the transactions provided for in Casino's accelerated safeguard plan approved by the Paris Commercial Court on 26 February 2024 (the " Accelerated Safeguard Plan ") and the accelerated safeguard plans of its concerned subsidiaries 1approved by the Paris Commercial Court on 26…
Nasdaq GlobeNewswire
28/03/2024
Altri Comunicati